 Quinolines
"Quinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011804
|
| MeSH Number(s) |
D03.633.100.810
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinolines".
Below are MeSH descriptors whose meaning is more specific than "Quinolines".
This graph shows the total number of publications written about "Quinolines" by people in this website by year, and whether "Quinolines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 3 | 3 | 6 | | 2007 | 0 | 1 | 1 | | 2008 | 4 | 0 | 4 | | 2009 | 2 | 3 | 5 | | 2010 | 3 | 3 | 6 | | 2011 | 2 | 5 | 7 | | 2012 | 1 | 3 | 4 | | 2013 | 3 | 1 | 4 | | 2014 | 5 | 4 | 9 | | 2015 | 3 | 2 | 5 | | 2016 | 4 | 2 | 6 | | 2017 | 1 | 0 | 1 | | 2018 | 2 | 1 | 3 | | 2019 | 4 | 2 | 6 | | 2020 | 1 | 2 | 3 | | 2021 | 3 | 3 | 6 | | 2022 | 2 | 2 | 4 | | 2023 | 1 | 1 | 2 | | 2024 | 4 | 5 | 9 | | 2025 | 6 | 13 | 19 | | 2026 | 1 | 5 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Quinolines" by people in Profiles.
-
Chalamalla AR, Baker E, Ryan KJ, Dowell A, Natt JR, Zemanick ET, Konstan MW, Mayer-Hamblett N, Acosta EP, Guimbellot JS. Impact of CFTR modulator concentrations on clinical response in cystic fibrosis. Eur Respir J. 2026 Jun; 67(6).
-
Muther EF, Gibson SL, Ford C, Duncan C, Riekert KA, Lyons E, Hoppe JE, Prickett M, Isenburg MV, Everhart RS. People with cystic fibrosis' experience of symptom burden while taking elexacaftor/tezacaftor/ivacaftor. Respir Med. 2026 Aug; 259:108908.
-
Nilsson T, Rasinski P, Sparrelid E, Tzortzakakis A, Tran TA, Smedby Ö, Axelsson R, Lubberink M, Holstensson M. Kinetic modelling of [68Ga]Ga-FAPI-46 PET in pancreaticobiliary lesions: distinguishing cancer from pancreatitis. Eur J Nucl Med Mol Imaging. 2026 Jul; 53(9):5549-5559.
-
Green N, Vu P, Xie J, Schwarzenberg SJ, Freedman S, Narkewicz M, Pittman J, Ratjen F, Rosenfeld M, Pope C, Duong J, Hoffman L, Heltshe S, Lusman SS. Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy. J Cyst Fibros. 2026 May; 25(3):489-494.
-
Corley MJ, Watanabe M, Pang APS, Dwaraka VB, Smith R, Samaneka W, Henn S, Munsiff S, Saumoy M, McCallum S, Fitch KV, Chu SM, Diggs MR, Aberg JA, Malvestutto CD, Fichtenbaum CJ, Currier JS, Zanni MV, Douglas PS, Lu MT, Landay AL, Erlandson KM, Ribaudo HJ, Grinspoon SK. Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial. Clin Infect Dis. 2026 Feb 04; 81(6):e560-e567.
-
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM. Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. Ann Am Thorac Soc. 2026 02 01; 23(2):241-251.
-
Abi-Aad SJ, Tsalatsanis A, Narkewicz M, Leung DH, Khalaf RT. The Impact of Elexacaftor-Tezacaftor-Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study. Pediatr Pulmonol. 2026 Feb; 61(2):e71522.
-
Castellani C, Mondejar-Lopez P, Van Goor F, Quon BS, Alghisi F, Fabrizzi B, Ramsey B, Taylor-Cousar JL, McKone EF, Tullis E, Weinstock TG, Tan V, Ahluwalia N, Mahic M, Liu L, Saayman S, Altshuler D, Waltz D, Mall MA, Fajac I. Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study. Am J Respir Crit Care Med. 2026 02 01; 212(2):327-337.
-
Lyons ER, Vigers T, Simoni M, Lynn C, Muther E. Body Image Perceptions and Elexacaftor/Tezacaftor/Ivacaftor (ETI) Use in Adolescents and Young Adults Living With Cystic Fibrosis. Pediatr Pulmonol. 2025 Dec; 60(12):e71418.
-
Sagel SD, Vu P, Heltshe SL, Solomon GM, Kelly A, Pittman J, Rosenfeld M, Ratjen F. Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis. J Cyst Fibros. 2026 May; 25(3):450-456.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|